Infliximab treatment in pachydermoperiostosis: a rare disease without an effective therapeutic option.
about
Identification of the Mutations in the Prostaglandin Transporter Gene, SLCO2A1 and Clinical Characterization in Korean Patients with Pachydermoperiostosis.Interleukin-6, tumor necrosis factor-alpha and receptor activator of nuclear factor kappa ligand are elevated in hypertrophic gastric mucosa of pachydermoperiostosis.Clinical, Biochemical, and Genetic Features of 41 Han Chinese Families With Primary Hypertrophic Osteoarthropathy, and Their Therapeutic Response to Etoricoxib: Results From a Six-Month Prospective Clinical Intervention.A novel recessive 15-hydroxyprostaglandin dehydrogenase mutation in a family with primary hypertrophic osteoarthropathy.
P2860
Infliximab treatment in pachydermoperiostosis: a rare disease without an effective therapeutic option.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Infliximab treatment in pachyd ...... effective therapeutic option.
@en
Infliximab treatment in pachyd ...... effective therapeutic option.
@nl
type
label
Infliximab treatment in pachyd ...... effective therapeutic option.
@en
Infliximab treatment in pachyd ...... effective therapeutic option.
@nl
prefLabel
Infliximab treatment in pachyd ...... effective therapeutic option.
@en
Infliximab treatment in pachyd ...... effective therapeutic option.
@nl
P2093
P1476
Infliximab treatment in pachyd ...... effective therapeutic option.
@en
P2093
Adriana F Zimmermann
Fabrício S Neves
Fernanda Vicente da Costa
Gláucio Ricardo Werner de Castro
Ivânio Alves Pereira
Sonia Cristina de Magalhães Souza Fialho
P304
P356
10.1097/RHU.0B013E3181DF91C6
P577
2010-06-01T00:00:00Z